Compare OFAL & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OFAL | RDHL |
|---|---|---|
| Founded | 2013 | 2009 |
| Country | United States | Israel |
| Employees | 10 | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 5.4M |
| IPO Year | N/A | 2012 |
| Metric | OFAL | RDHL |
|---|---|---|
| Price | $0.24 | $0.81 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 588.9K | 154.9K |
| Earning Date | 06-03-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.21 | $0.71 |
| 52 Week High | $3.37 | $3.31 |
| Indicator | OFAL | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 30.51 | 36.86 |
| Support Level | $0.21 | $0.76 |
| Resistance Level | $0.46 | $0.89 |
| Average True Range (ATR) | 0.03 | 0.09 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 29.00 | 11.29 |
OFA Group, through its subsidiary, provides architectural services, including design and fit-out services for commercial and residential buildings in Hong Kong. The design service includes both the consultation with staff and the actual design work and the company provides a specific conceptualized design with layout plans, detailed design drawings, advice relating to, among other things, budgetary consideration, optimal use of space, the materials, fittings, furniture, appliances and other items to be used to produce a preliminary design plan and quotation. Its works include installing protective materials to cover floors or walls, installing or constructing partition walls, windows, window frames, and decorative fittings, furniture or fixtures, installing plumbing systems, etc.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.